Category Archives: Generic drug

How Much? A Battle Over The Cost Of The New Hepatitis C Drugs

Source: Pharmalive As excitement mounts among physicians and investors over a new crop of drugs for treating hepatitis C, there is also concern that patients in developing countries may not have sufficient access due to high prices. But a recent … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, Hepatitis - C, HIV/Aids, IP Rights, patent | Tagged , | 1 Comment

South Africa Embraces Compulsory Licensing Over AIDS Crisis

Source: Pharmalive Two months after releasing a draft policy for governing intellectual property, South Africa has decided to amend its patent legislation so the government can use parallel importing and compulsory licensing that is allowed under international agreements, according to … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, HIV/Aids, IP Rights, patent, Right to Health, South Africa's Patent Act, TRIPS, TRIPS flexibilities, WTO | Tagged | Leave a comment

MSFquote–Documents disclosed by WikiLeaks add to doubts over U.S.-led Pacific Rim trade deal in 2013

Source: Edmonton Journal The aid group Doctors Without Borders objected to stringent protections for patents on pharmaceuticals that would benefit drug companies, one of the chief objectives of the trade talks. The document “confirms that the U.S. government continues to … Continue reading

Posted in access to medicines, Generic drug, HIV/Aids, IP Rights, IPR Enforcement, patent, TB, TPPA, Trans-Pacific Partnership Agreement | Leave a comment

WikiLeaks shines rare light onto US trade negotiations

Source: Aljazeera America Leak details intellectual property rights deal in Trans-Pacific Partnership under negotiation between US and 10 nations US President Barack Obama poses for a photograph with Trans-Pacific Partnership leaders. In its latest document dump, WikiLeaks unearthed what it … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, IP Rights, IPR Enforcement, Medicine Patent Pool, Right to Health, Trans-Pacific Partnership Agreement, transparency | Tagged , , | Leave a comment

Will The New Hepatitis C Drugs Trigger A Battle Over Cost?

Source: Forbes As excitement mounts among physicians and investors over a new batch of drugs for treating hepatitis C, there is also concern that patients in developing countries may not have sufficient access due to high prices. But a recent … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, HIV/Aids | Tagged , , , , | Leave a comment

The Op-Ed: What Patent Reform In Brazil And South Africa Can Mean

Source: Pharmalot In recent months, two countries with large economies and large populations both took steps to rework their patent laws, in part, to expand access to medicines. The moves come amid increasing concerns that treatments for certain ailments, such … Continue reading

Posted in access to medicines, Brazil Patent Reform, Doha Declaration, Draft South Africa Policy on IP 2013, Generic drug, HIV/Aids, IP Rights, IPR Enforcement, patent, Right to Health, TRIPS, TRIPS flexibilities, Voluntary License, WTO | Tagged | Leave a comment

South Africa ‘seeks balance’ between intellectual property, public health

Source: Business Live THE government’s policy on intellectual property (IP), currently under discussion, would seek to strike a balance between the needs of public health and the interests of innovative pharmaceutical companies, Trade and Industry Minister Rob Davies said on … Continue reading

Posted in access to medicines, Generic drug, Hepatitis - C, HIV/Aids, IP Rights, IPR Enforcement, patent, patent cliff, patent evergreening, Patent examination system, South Africa's Patent Act, TB, WTO | Leave a comment

How drug companies price patients out of survival

Source: Salon As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another health care battle rages in village clinics and corporate boardrooms. Behind the seductive commercials for breakthrough treatments, multinational brands … Continue reading

Posted in access to medicines, Compulsory Licensing, data exclusivity, EU-India FTA, FTAs, Generic drug, Government Use License, HIV/Aids, Indian Patent Law, IP Rights, IPR Enforcement, Medicine Patent Pool, NAFTA, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TB, Trans-Pacific Partnership Agreement, TRIPS, TRIPS flexibilities, WHO, WTO | Tagged , | Leave a comment

Brazil’s sick of patent exploitation

Source: Mail and Guardian  The country is fighting the intellectual property laws that hiked up the cost of its HIV programme. In 1996, in reaction to the enormity of the country’s HIV epidemic and citing its constitutional obligation to protect … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, IP Rights, patent, Patent examination system, Right to Health, TRIPS, TRIPS flexibilities, WTO | Leave a comment

Join the fight for more affordable medicines!!17 Oct Pretoria, South Africa

Comrades, join the fight for more affordable medicines!! On 17th October, join the Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION 27 to tell the Department for Trade and Industry to once and for all, Fix our Patent Laws!! When: Thursday … Continue reading

Posted in access to medicines, Draft South Africa Policy on IP 2013, Generic drug, IP Rights, patent | Tagged | Leave a comment